Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Failing treatment of multidrug-resistant tuberculosis: a matter of definition.

Chesov D, Alexandru S, Crudu V, Ciobanu N, Botnaru V, Heyckendorf J, Lange C.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):522-524. doi: 10.5588/ijtld.18.0756. No abstract available.

PMID:
31064633
2.

Assessing tuberculosis control priorities in high-burden settings: a modelling approach.

Vesga JF, Hallett TB, Reid MJA, Sachdeva KS, Rao R, Khaparde S, Dave P, Rade K, Kamene M, Omesa E, Masini E, Omale N, Onyango E, Owiti P, Karanja M, Kiplimo R, Alexandru S, Vilc V, Crudu V, Bivol S, Celan C, Arinaminpathy N.

Lancet Glob Health. 2019 May;7(5):e585-e595. doi: 10.1016/S2214-109X(19)30037-3. Epub 2019 Mar 20. Erratum in: Lancet Glob Health. 2019 Sep;7(9):e1179.

3.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
4.

Beyond the SNP Threshold: Identifying Outbreak Clusters Using Inferred Transmissions.

Stimson J, Gardy J, Mathema B, Crudu V, Cohen T, Colijn C.

Mol Biol Evol. 2019 Mar 1;36(3):587-603. doi: 10.1093/molbev/msy242.

PMID:
30690464
5.

Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis.

Santos VS, Goletti D, Kontogianni K, Adams ER, Molina-Moya B, Dominguez J, Crudu V, Martins-Filho PRS, Ruhwald M, Lawson L, Bimba JS, Garcia-Basteiro AL, Petrone L, Kabeer BS, Reither K, Cuevas LE.

Clin Microbiol Infect. 2019 Feb;25(2):169-177. doi: 10.1016/j.cmi.2018.07.017. Epub 2018 Aug 2.

6.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
7.

Cost analysis of rapid diagnostics for drug-resistant tuberculosis.

Groessl EJ, Ganiats TG, Hillery N, Trollip A, Jackson RL, Catanzaro DG, Rodwell TC, Garfein RS, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

BMC Infect Dis. 2018 Mar 2;18(1):102. doi: 10.1186/s12879-018-3013-0.

8.

Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the katG 315T mutation.

Chesov D, Ciobanu N, Lange C, Schön T, Heyckendorf J, Crudu V.

Eur Respir J. 2017 Oct 12;50(4). pii: 1701752. doi: 10.1183/13993003.01752-2017. Print 2017 Oct. No abstract available.

9.

High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.

Chesov D, Ciobanu N, Lange C, Heyckendorf J, Crudu V.

Eur Respir J. 2017 Oct 12;50(4). pii: 1701340. doi: 10.1183/13993003.01340-2017. Print 2017 Oct. No abstract available.

10.

The TB Portals: an Open-Access, Web-Based Platform for Global Drug-Resistant-Tuberculosis Data Sharing and Analysis.

Rosenthal A, Gabrielian A, Engle E, Hurt DE, Alexandru S, Crudu V, Sergueev E, Kirichenko V, Lapitskii V, Snezhko E, Kovalev V, Astrovko A, Skrahina A, Taaffe J, Harris M, Long A, Wollenberg K, Akhundova I, Ismayilova S, Skrahin A, Mammadbayov E, Gadirova H, Abuzarov R, Seyfaddinova M, Avaliani Z, Strambu I, Zaharia D, Muntean A, Ghita E, Bogdan M, Mindru R, Spinu V, Sora A, Ene C, Vashakidze S, Shubladze N, Nanava U, Tuzikov A, Tartakovsky M.

J Clin Microbiol. 2017 Nov;55(11):3267-3282. doi: 10.1128/JCM.01013-17. Epub 2017 Sep 13.

11.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

12.

Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.

Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; for TBNET ‡.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1222-1224. doi: 10.1164/rccm.201612-2585LE. No abstract available.

PMID:
28323453
13.

MDR-TB in Eastern Europe in the era of the TB elimination action framework.

Dudnyk A, Butov D, Crudu V, Lange C, Chesov D.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):2-3. doi: 10.5588/ijtld.16.0732. No abstract available.

PMID:
28157456
14.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

15.

Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis.

Eldholm V, Pettersson JH, Brynildsrud OB, Kitchen A, Rasmussen EM, Lillebaek T, Rønning JO, Crudu V, Mengshoel AT, Debech N, Alfsnes K, Bohlin J, Pepperell CS, Balloux F.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13881-13886. Epub 2016 Nov 21.

16.

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages.

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Henry Boom W, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S.

Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31.

17.

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBNET.

N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274. No abstract available.

18.

Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis.

Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

BMC Infect Dis. 2016 Aug 31;16:458. doi: 10.1186/s12879-016-1781-y.

19.

Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study.

Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM.

J Clin Microbiol. 2016 Aug;54(8):2058-67. doi: 10.1128/JCM.00535-16. Epub 2016 May 25.

20.

Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, Rodrigues C, Victor TC, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3994-4004. doi: 10.1128/AAC.00222-16. Print 2016 Jul.

21.

A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis.

Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

Int J Tuberc Lung Dis. 2016 May;20(5):631-7. doi: 10.5588/ijtld.15.0788.

22.

In reply.

Merker M, Crudu V, Noroc E, Romancenco E, Chesov D, Günther G, Niemann S, Lange C.

Int J Tuberc Lung Dis. 2016 Mar;20(3):424. doi: 10.5588/ijtld.15.1024-2. No abstract available.

PMID:
27046728
23.

MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.

Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC.

J Clin Microbiol. 2016 Apr;54(4):912-8. doi: 10.1128/JCM.02505-15. Epub 2016 Jan 13.

24.

Nosocomial transmission of multidrug-resistant tuberculosis.

Crudu V, Merker M, Lange C, Noroc E, Romancenco E, Chesov D, Günther G, Niemann S.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1520-3. doi: 10.5588/ijtld.15.0327.

PMID:
26614195
25.

Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

ElMaraachli W, Slater M, Berrada ZL, Lin SY, Catanzaro A, Desmond E, Rodrigues C, Victor TC, Crudu V, Gler MT, Rodwell TC.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1222-6. doi: 10.5588/ijtld.14.0936.

26.

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis.

Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K.

PLoS One. 2015 Aug 31;10(8):e0136861. doi: 10.1371/journal.pone.0136861. eCollection 2015.

27.

Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.

Torres JN, Paul LV, Rodwell TC, Victor TC, Amallraja AM, Elghraoui A, Goodmanson AP, Ramirez-Busby SM, Chawla A, Zadorozhny V, Streicher EM, Sirgel FA, Catanzaro D, Rodrigues C, Gler MT, Crudu V, Catanzaro A, Valafar F.

Emerg Microbes Infect. 2015 Jul;4(7):e42. doi: 10.1038/emi.2015.42. Epub 2015 Jul 15.

28.

Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing.

Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM.

PLoS One. 2015 May 13;10(5):e0126626. doi: 10.1371/journal.pone.0126626. eCollection 2015.

29.

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.

Garfein RS, Catanzaro DG, Rodwell TC, Avalos E, Jackson RL, Kaping J, Evasco H, Rodrigues C, Crudu V, Lin SY, Groessl E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valafar F, Channick J, Qian L, Catanzaro A.

Int J Tuberc Lung Dis. 2015 Apr;19(4):420-7. doi: 10.5588/ijtld.14.0488. Erratum in: Int J Tuberc Lung Dis. 2015 Jul;19(7):874. Groessel, E [corrected to Groessl, E].

30.

Combined antigen-specific interferon-γ and interleukin-2 release assay (FluoroSpot) for the diagnosis of Mycobacterium tuberculosis infection.

Chesov D, Lange C, Daduna F, Crudu V, Preyer R, Ernst M, Kalsdorf B.

PLoS One. 2015 Mar 18;10(3):e0120006. doi: 10.1371/journal.pone.0120006. eCollection 2015.

31.

Prognostic significance of novel katG mutations in Mycobacterium tuberculosis.

Valafar F, Ramirez-Busby SM, Torres J, Paul LV, Rodwell TC, Victor TC, Rodrigues C, Gler MT, Crudu V, Catanzaro T.

Int J Mycobacteriol. 2015 Mar;4(Suppl 1):51-52. Epub 2015 Jan 7.

32.

Multidrug-resistant tuberculosis in Europe, 2010-2011.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Emerg Infect Dis. 2015 Mar;21(3):409-16. doi: 10.3201/eid2103.141343.

33.

Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.

Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rüsch-Gerdes S, Mokrousov I, Aleksic E, Allix-Béguec C, Antierens A, Augustynowicz-Kopeć E, Ballif M, Barletta F, Beck HP, Barry CE 3rd, Bonnet M, Borroni E, Campos-Herrero I, Cirillo D, Cox H, Crowe S, Crudu V, Diel R, Drobniewski F, Fauville-Dufaux M, Gagneux S, Ghebremichael S, Hanekom M, Hoffner S, Jiao WW, Kalon S, Kohl TA, Kontsevaya I, Lillebæk T, Maeda S, Nikolayevskyy V, Rasmussen M, Rastogi N, Samper S, Sanchez-Padilla E, Savic B, Shamputa IC, Shen A, Sng LH, Stakenas P, Toit K, Varaine F, Vukovic D, Wahl C, Warren R, Supply P, Niemann S, Wirth T.

Nat Genet. 2015 Mar;47(3):242-9. doi: 10.1038/ng.3195. Epub 2015 Jan 19.

PMID:
25599400
34.

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis.

Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A.

Trials. 2014 Nov 6;15:434. doi: 10.1186/1745-6215-15-434.

35.

Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Ajbani K, Lin SY, Rodrigues C, Nguyen D, Arroyo F, Kaping J, Jackson L, Garfein RS, Catanzaro D, Eisenach K, Victor TC, Crudu V, Gler MT, Ismail N, Desmond E, Catanzaro A, Rodwell TC.

Antimicrob Agents Chemother. 2015 Jan;59(1):414-20. doi: 10.1128/AAC.03614-14. Epub 2014 Nov 3.

36.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET.

Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.

37.

High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.

Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T.

Eur Respir J. 2014 Apr;43(4):1132-41. doi: 10.1183/09031936.00203613. Epub 2014 Feb 20.

38.

Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.

Trollip AP, Moore D, Coronel J, Caviedes L, Klages S, Victor T, Romancenco E, Crudu V, Ajbani K, Vineet VP, Rodrigues C, Jackson RL, Eisenach K, Garfein RS, Rodwell TC, Desmond E, Groessl EJ, Ganiats TG, Catanzaro A.

Int J Tuberc Lung Dis. 2014 Feb;18(2):227-32. doi: 10.5588/ijtld.13.0229.

39.

Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.

Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A.

J Clin Microbiol. 2014 Mar;52(3):781-9. doi: 10.1128/JCM.02701-13. Epub 2013 Dec 18.

40.

Periodontal disease is an independent predictor of intracardiac calcification.

Pressman GS, Qasim A, Verma N, Miyamae M, Arishiro K, Notohara Y, Crudu V, Figueredo VM.

Biomed Res Int. 2013;2013:854340. doi: 10.1155/2013/854340. Epub 2013 Sep 11.

41.

Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis.

Hoshide M, Qian L, Rodrigues C, Warren R, Victor T, Evasco HB 2nd, Tupasi T, Crudu V, Douglas JT.

J Clin Microbiol. 2014 May;52(5):1322-9. doi: 10.1128/JCM.00857-13. Epub 2013 Jun 19.

42.

Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova.

Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T.

Int J Tuberc Lung Dis. 2013 Mar;17(3):373-80. doi: 10.5588/ijtld.12.0464.

43.

Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country.

Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M, Cohen T.

Eur Respir J. 2013 Nov;42(5):1291-301. doi: 10.1183/09031936.00111812. Epub 2012 Oct 25.

44.

Middle-of-the-night PCI does not affect subsequent day PCI success and complication rates by the same operator.

Crudu V, Sartorius J, Berger P, Scott T, Skelding K, Blankenship J.

Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1149-54. doi: 10.1002/ccd.23504. Epub 2012 Mar 30.

PMID:
22473815
45.

First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances.

Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N.

J Clin Microbiol. 2012 Apr;50(4):1264-9. doi: 10.1128/JCM.05903-11. Epub 2012 Feb 1.

46.

Complications related to access site after percutaneous coronary interventions: are the adverse events underreported?

Crudu V, Blankenship J, Berger P, Scott T, Skelding K.

Catheter Cardiovasc Interv. 2011 Apr 1;77(5):643-7. doi: 10.1002/ccd.22759. Epub 2011 Mar 8.

PMID:
20824761
47.

Can total cardiac calcium predict the coronary calcium score?

Pressman GS, Crudu V, Parameswaran-Chandrika A, Romero-Corral A, Purushottam B, Figueredo VM.

Int J Cardiol. 2011 Jan 21;146(2):202-6. doi: 10.1016/j.ijcard.2009.06.057. Epub 2009 Jul 17.

PMID:
19615766
48.

Increasing tuberculosis case detection: lessons from the Republic of Moldova.

Soltan V, Henry AK, Crudu V, Zatusevski I.

Bull World Health Organ. 2008 Jan;86(1):71-6.

49.

Resistance to anti-tuberculosis drugs and practices in drug susceptibility testing in Moldova, 1995-1999.

Crudu V, Arnadottir T, Laticevschi D.

Int J Tuberc Lung Dis. 2003 Apr;7(4):336-42.

PMID:
12729338

Supplemental Content

Support Center